Literature DB >> 18784744

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.

M Rohrbacher, U Berger, A Hochhaus, G Metzgeroth, K Adam, T Lahaye, S Saussele, M C Müller, J Hasford, H Heimpel, R Hehlmann.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18784744     DOI： 10.1038/leu.2008.245

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  22 in total

Review 1.  Are ongoing trials on hematologic malignancies still excluding older subjects?

Authors:  Antonio Cherubini; Francesca Pierri; Beatrice Gasperini; Elisa Zengarini; Annarita Cerenzia; Elisabetta Bonifacio; Flavio Falcinelli; Fabrizia Lattanzio
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

Review 2.  The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.

Authors:  Michael J Mauro; Catherine Davis; Teresa Zyczynski; H Jean Khoury
Journal:  Ther Adv Hematol       Date:  2015-02

3.  The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Authors:  V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann
Journal:  Leukemia       Date:  2015-03-18       Impact factor: 11.528

Review 4.  First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.

Authors:  Gabriele Gugliotta; Fausto Castagnetti; Michela Apolinari; Sara Pirondi; Michele Cavo; Michele Baccarani; Gianantonio Rosti
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 5.  Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.

Authors:  Uday Deotare; Dennis Dong Hwan Kim; Jeffrey H Lipton
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

6.  Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Authors:  Susanne Saussele; Marie-Paloma Krauss; Rüdiger Hehlmann; Michael Lauseker; Ulrike Proetel; Lida Kalmanti; Benjamin Hanfstein; Alice Fabarius; Doris Kraemer; Wolfgang E Berdel; Martin Bentz; Peter Staib; Maike de Wit; Martin Wernli; Florian Zettl; Holger F Hebart; Markus Hahn; Jochen Heymanns; Ingo Schmidt-Wolf; Norbert Schmitz; Michael J Eckart; Winfried Gassmann; Andrea Bartholomäus; Antonio Pezzutto; Elisabeth Oppliger Leibundgut; Dominik Heim; Stefan W Krause; Andreas Burchert; Wolf-Karsten Hofmann; Joerg Hasford; Andreas Hochhaus; Markus Pfirrmann; Martin C Müller
Journal:  Blood       Date:  2015-04-27       Impact factor: 22.113

7.  Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.

Authors:  Roberto Latagliata; Dario Ferrero; Alessandra Iurlo; Francesco Cavazzini; Fausto Castagnetti; Elisabetta Abruzzese; Carmen Fava; Massimo Breccia; Mario Annunziata; Fabio Stagno; Mario Tiribelli; Gianni Binotto; Giovanna Mansueto; Antonella Gozzini; Sabina Russo; Laura Cavalli; Enrico Montefusco; Gabriele Gugliotta; Michele Cedrone; Antonella Russo Rossi; Paolo Avanzini; Patrizia Pregno; Endri Mauro; Antonio Spadea; Francesca Celesti; Gianfranco Giglio; Alessandro Isidori; Monica Crugnola; Elisabetta Calistri; Federica Sorà; Stefano Storti; Ada D'Addosio; Giovanna Rege-Cambrin; Luigiana Luciano; Giuliana Alimena
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

8.  Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Authors:  Martin Höglund; Fredrik Sandin; Karin Hellström; Mats Björeman; Magnus Björkholm; Mats Brune; Arta Dreimane; Marja Ekblom; Sören Lehmann; Per Ljungman; Claes Malm; Berit Markevärn; Kristina Myhr-Eriksson; Lotta Ohm; Ulla Olsson-Strömberg; Anders Själander; Hans Wadenvik; Bengt Simonsson; Leif Stenke; Johan Richter
Journal:  Blood       Date:  2013-07-10       Impact factor: 22.113

9.  Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection.

Authors:  Michael J Webb; Claire L Barrett; Christel Pretorius; Magdalena F van Jaarsveld; Vernon J Louw
Journal:  Int J Hematol       Date:  2012-04-20       Impact factor: 2.319

10.  Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

Authors:  Hana Klamová; Kateřina Machová Poláková; Jan Mužík; Zdeněk Ráčil; Daniela Záčková; Kateřina Steinerová; Michal Karas; Edgar Faber; Eva Demečková; Zuzana Michalovičová-Sninská; Jaroslava Voglová; Ludmila Demitrovičová; Eva Mikušková; Elena Tóthová; Juraj Chudej; Imrich Markuljak; Eduard Cmunt; Jana Moravcová; Dana Dvořáková; Kyra Michalová; Marie Jarošová; Markéta Marková Sťastná; Petr Cetkovský; Ladislav Dušek; Vladimír Koza; Marek Trněný; Karel Indrák
Journal:  Cancer Med       Date:  2013-02-21       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.